|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"de marinis f"
Showing items 1-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
|
John, T.;Groh�, C.;Goldman, J.W.;Shepherd, F.A.;de, Marinis F.;Kato, T.;Wang, Q.;Su, W.-C.;Choi, J.H.;Sriuranpong, V.;Melotti, B.;Fidler, M.J.;Chen, J.;Albayaty, M.;Stachowiak, M.;Taggart, S.;Wu, Y.-L.;Tsuboi, M.;Herbst, R.S.;Majem, Majem M. |
| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2022-06-27T06:59:32Z |
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
|
Wu Y.-L.; Tsuboi M.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; De Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2022-06-27T06:59:30Z |
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
|
Wu Y.-L.; John T.; Grohe C.; Majem M.; Goldman J.W.; Kim S.-W.; Kato T.; Laktionov K.; Vu H.V.; Wang Z.; Lu S.; Lee K.Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Atasoy A.; Herbst R.S.; Tsuboi M. |
| 臺大學術典藏 |
2022-06-27T06:59:29Z |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
|
Majem M.; Goldman J.W.; John T.; Grohe C.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.V.; Lu S.; Li S.; Lee K.Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Atagi S.; Zeng L.; Kulkarni D.; Medic N.; Tsuboi M.; Herbst R.S.; Wu Y.-L. |
| 臺大學術典藏 |
2021-05-02T03:29:23Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.;Tsuboi M.;He J.;John T.;Grohe C.;Majem M.;Goldman J.W.;Laktionov K.;Kim S.-W.;Kato T.;Vu H.-V.;Lu S.;Lee K.-Y.;Akewanlop C.;Chong-Jen Yu;De Marinis F.;Bonanno L.;Domine M.;Shepherd F.A.;Zeng L.;Hodge R.;Atasoy A.;Rukazenkov Y.;Herbst R.S.; Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 臺大學術典藏 |
2020-05-26T09:27:14Z |
Vandetanib plus pemetrexed for the second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial
|
De Boer R.H;Arrieta ?;Chih-Hsin Yang;Gottfried M;Chan V;Raats J;De Marinis F;Abratt R.P;Wolf J;Blackhall F.H;Langmuir P;Milenkova T;Read J;Vansteenkiste J.F.; De Boer R.H; Arrieta ?; CHIH-HSIN YANG; Gottfried M; Chan V; Raats J; De Marinis F; Abratt R.P; Wolf J; Blackhall F.H; Langmuir P; Milenkova T; Read J; Vansteenkiste J.F. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
|
Lux-Lung 5 Investigators;Serwatowski P;Kazarnowicz A;Jaskiewicz P;Palomino O.L.M;Pantigoso W.R;Barreda R.L.A;S?nchez J.F.S;Gans S;Herder G;Dingemans A.-M;Stigt J;Aerts J;Baca O.P;Luna G.A;Perez J.L.G;Delgado F.G;Cruciani G;Ceresoli G.L;Platania M;Milandri C;Gridelli C;Bearz A;Bidoli P;Migliorino M.R;Stemmer S;Gottfried M;Onn A;Nagarkar R.V;Dadhich H;Sharma L;Venkatesan S;Jain M;Prabhash K;Sarosi V;Strausz J;Tehenes S;Mark Z;Wiewrodt R;Dickgreber N;Huber R;Von Pawel J;Laack E;Keilholz U;Faehling M;Wehler T;Thomas M;Coudert B;Rotarski M;Gervais R;Fournel P;Bennouna J;Planchard D;Perol M;Sibilot D.M;Zalcman G;Chouaid C;Cadranel J;Alanko T;Riska H;Zadra C.A;Garicochea B;Zereu M;Lu S;Zhang Y;Huang J;Feng J;Qin S;Cheng Y;Liu X;Wu Y;Lin X;Thropay J;Meza L;Gurtler J;Summers Y;Upadhyay S;Brown E;Talbot T;Toy E;Spicer J;Popat S;Mitra S;Shah R;Polishchuk I;Bondarenko I;Ponomarova O;Popovych O;Vinnyk Y;Hsieh R.-K;Ho C.-L;Huang M.-S;Su W.-C;Tsao T.C.-Y;Chang G.-C;Tsai Y.-H;Chen Y.-M;Hsia T.-C;Yang C.-H;Kim Y.-C;Han J.-Y;Kim J.-H;Park K;Kim S.-W;Kim D.-W;Felip E;Cobo M;Lianes P;Campelo R.G;Camps C;Larriba J.L.G;Garrido P;Ragulin Y;Orlov S;Karaseva N;Lubennikov V;Jassem J;Szczesna A;Huang C;Wang J;Zhou C;Vercauter P;Delval L;Lambrechts M;Galdermans D;Carestia L;Bustin F;Humblet Y;Greil R;Mainwaring P;Crombie C;Underhill C;Parente P;Mclachlan S.-A;Richardet M;Blajman C;Zarba J.J;Recondo G;Martin C.M;Bagnes C;Planchard D;Chand V.K;Wang B;Zhou C;Wiewrodt R;Vinnyk Y;Strausz J;Lu S;Liu X;Kim D.-W;Grossi F;Feng J.-F;De Marinis F;Chouaid C;Chen Y.-M;Bennouna J;Kim J.-H;Park K;Chih-Hsin Yang;Schuler M; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators; Schuler M; CHIH-HSIN YANG; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
|
Ou S.-H.I.;Kotb A;Gupta R;Liu S;Schulz M;De Marinis F;Kim D.-W;Dingemans A.-M.C;Chih-Hsin Yang;Crin? L;Barlesi F;Shaw A.T;Gadgeel S; Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials
|
Jänne P.A; CHIH-HSIN YANG; Mitsudomi T; Johnson M; Cantarini M; Chih-Hsin Yang;J?nne P.A;Mitsudomi T;Johnson M;Cantarini M;Hodge R;Morabito A;Felip E;De Marinis F;Crin? L;Bazhenova L;Ahn M.-J;Shepherd F.A;Tsai C.-M;Goss G; Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
| 臺大學術典藏 |
2014 |
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International expert panel meeting of the Italian association of thoracic oncology
|
Gridelli C;De Marinis F;Cappuzzo F;Di Maio M;Hirsch F.R;Mok T;Morgillo F;Rosell R;Spigel D.R;Chih-Hsin Yang;Ciardiello F.; Gridelli C; De Marinis F; Cappuzzo F; Di Maio M; Hirsch F.R; Mok T; Morgillo F; Rosell R; Spigel D.R; CHIH-HSIN YANG; Ciardiello F. |
Showing items 1-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
